206 results on '"Solit, D"'
Search Results
2. 645P Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors
3. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era
4. Oncologist use and perception of large panel next-generation tumor sequencing
5. V600E B-Raf Requires the Hsp90 Chaperone for Stability and Is Degraded in Response to Hsp90 Inhibitors
6. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF
7. 2231O Pan-cancer assessment of the impact of intronic variants on cancer development and progression
8. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
9. FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies
10. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
11. P-266 Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI)
12. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration
13. Perturbation biology models predict c-Myc as an effective co-target in RAF inhibitor resistant melanoma cells
14. Poor survival after resection of early gastric cancer: extremes of survivorship analysis reveal distinct genomic profile
15. First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
16. Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT ‘basket’ trial
17. Poor survival after resection of early gastric cancer: extremes of survivorship analysis reveal distinct genomic profile.
18. Spécificités moléculaires des tumeurs de la voie excrétrice urinaire supérieure
19. Classification phylogénétique des récidives vésicales après tumeur de la voie excrétrice urinaire supérieure
20. Comparing metastatic (M) young onset (YO) colorectal cancer (CRC) with average onset (AO): Do they differ clinically and genetically?
21. Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer
22. OA 10.05 Non-Invasive Molecular Profiling in NSCLC by Targeted and Whole Exome Analysis of Plasma cfDNA
23. OA 14.05 Phase 2 Basket Trial of Ado-Trastuzumab Emtansine in Patients with HER2 Mutant or Amplified Lung Cancers
24. Targeting ERBB2 mutations in urothelial carcinoma
25. Abstract PD2-08: Neratinib + fulvestrant inERBB2-mutant, HER2–non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial
26. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer
27. 817P - First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
28. Kras mutations and resistance to anti-egfr treatment
29. Abstract P4-14-21: A phase I trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer (MBC)
30. A role for Id proteins in mammary gland physiology and tumorigenesis
31. 591P - Comparing metastatic (M) young onset (YO) colorectal cancer (CRC) with average onset (AO): Do they differ clinically and genetically?
32. 2189 Early onset colorectal cancer - does the difference lie in epigenetics?
33. 2650 Assessment of genomic alterations in bladder adenocarcinoma and urachal adenocarcinoma
34. 838 - Targeting ERBB2 mutations in urothelial carcinoma
35. 75 Loss of PTEN leads to acquired resistance to the PI3Ka inhibitor BYL719: a case of convergent evolution under selective therapeutic pressure
36. 22 Determinants of RAF Inhibitor Resistance
37. P2.08 Emergence of Kras Mutations and Acquired Resistance to Anti Egfr Therapy in Colorectal Cancer
38. Therapeutics
39. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF
40. Comparative genomic analysis of primary versus metastasis in colorectal carcinomas.
41. Alterations in genes regulating cell cycle and apoptosis in high-grade urothelial carcinoma.
42. Antitumor activity of SNX-2112, a synthetic heat shock protein 90 inhibitor, in malignancies with amplification of the MET oncogene.
43. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
44. Phase I/II study of docetaxel and 153Sm for castrate metastatic prostate cancer (CMPC): Summary of dose-escalation cohorts and first report on the expansion cohort
45. A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel
46. PIK3CA and AKT1 mutations are independent in invasive breast cancer.
47. Phase I study of docetaxel (Tax) and 153Sm repetitively administered for castrate metastatic prostate cancer (CMPC)
48. Development and application of Hsp90 inhibitors
49. 159 INVITED Targeting MEK in tumors with BRAF and RAS mutations
50. Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not HSP90 inhibitors in models of HER2 amplified breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.